Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes

Core Insights - Thermo Fisher Scientific has launched the PPD™ CorEvitas™ Obesity Registry to gather real-world evidence on obesity management therapies, focusing on long-term effectiveness, safety, and patient experience [1][3] - The registry aims to collect detailed physician and patient-reported outcomes to enhance understanding of disease progression and treatment responses [4] Industry Context - Obesity is a chronic disease affecting over 100 million adults in the U.S., with severe obesity impacting more than 22 million adults [2] - The global economic burden of overweight and obesity is projected to reach $3 trillion annually by 2030, increasing to over $18 trillion by 2060 [2] Registry Details - The CorEvitas Obesity Registry is the 15th independent registry under PPD™ CorEvitas™ Clinical Registries, which is part of Thermo Fisher's clinical research business [4] - The registry will provide insights that inform clinical practice, guide future research, and support evidence-based strategies for obesity management [4][5] Company Overview - Thermo Fisher Scientific is a leader in serving science with annual revenues exceeding $40 billion, providing innovative technologies and services across various sectors [7]